Cofoe Medical Technology Co., Ltd. reported first-half 2026 revenue of RMB2.07 billion, up 38.5% year-on-year, driven by continued expansion across core product lines and the consolidation of recently acquired Humana Medical. Gross profit climbed 51.3% to RMB1.13 billion, lifting the gross margin by 4.6 ppts to 54.6%.
\n\nNet profit attributable to shareholders rose 20.8% to RMB202.26 million. Earnings per share came in at RMB0.95 basic and RMB0.94 diluted. Management declared an interim cash dividend of RMB0.60 per 10 shares (tax inclusive), equivalent to a total payout of roughly RMB136.28 million, pending shareholder approval.
\n\nOperating cash inflow reached RMB262.41 million, 25.3% lower than a year earlier owing to higher inventory and marketing spend. Net cash rose sharply following the May 2026 Hong Kong listing, which raised HKD1.01 billion (about RMB910 million) and lifted cash and bank balances to RMB2.48 billion at period-end, up 74.1% from end-2025. The current ratio improved to 2.63, while the gearing ratio eased to 25.4%.
\n\nAll five business segments—health monitoring, rehabilitation aids, respiratory support, medical care and TCM physiotherapy—recorded solid growth. Revenue from the top five products advanced 50.0% year-on-year, and overseas sales doubled to RMB210 million, accounting for 10.1% of group turnover.
\n\nR&D investment expanded 29.9% to RMB52.01 million, reflecting initiatives such as the new AI Research Institute, launch of the C11 AI-powered ventilator, and progress in continuous glucose monitoring systems and next-generation bone-conduction hearing aids. The company holds around 700 granted patents and is advancing digital factory upgrades across four production bases.
\n\nCapital expenditure totaled RMB81.40 million. Interest-bearing debt stood at RMB758.26 million, all short-term and RMB-denominated, with no asset pledges. Significant capital commitments amounted to RMB156.18 million, mainly for plant and equipment.
\n\nSubsequent to 30 June, Cofoe Medical repurchased 1.57 million A shares for RMB83.32 million under its up-to-RMB200 million buyback program and proposed the above-mentioned interim dividend.
\n\nManagement reiterated its focus on AI-driven product upgrades, omnichannel expansion, and accelerated internationalisation to capture rising demand for household medical devices amid China’s ageing population and broader health-consumption trends.